Key result
Anthracycline and cyclophosphamide therapy is linked to reduced LVEF and significant ECG prolongation.
Why the study?
Breast cancer patients treated with anthracyclines and cyclophosphamide are at risk of cardiotoxicity that may not be detected by routine ECG, and Holter ECG may provide earlier detection of cardiac effects.
Does Holter ECG detect early electrical and functional cardiac changes in breast cancer patients receiving their first cycle of anthracyclines and cyclophosphamide therapy?
Observational (n=144)
Does Holter ECG detect early electrical and functional cardiac changes in breast cancer patients receiving their first cycle of anthracyclines and cyclophosphamide therapy?
Answers are grounded in this paper and cite their sources.
Holter ECG and echocardiography can detect early subclinical cardiotoxicity, including electrical and functional changes, in breast cancer patients after just one cycle of anthracycline and cyclophosphamide therapy.
Background: Breast cancer patients treated with anthracyclines and cyclophosphamide are at risk of cardiotoxicity, which may not be detected by routine electrocardiogram (ECG). Holter ECG provides continuous monitoring that can capture early or transient ECG changes, offering a valuable tool for the early detection of chemotherapy-induced cardiac effects. Aim: To determine the value of Holter ECG in detecting ECG changes during sessions of anthracycline and cyclophosphamide therapy in breast cancer patients. Methods: This prospective study was carried out on 144 patients with breast cancer and with no structural heart diseases before the chemotherapy, as proved by objective tools, who received the first cycle of anthracyclines and cyclophosphamide therapy. Results: E, A, and E/E’ were significantly higher after therapy than before, while ejection fraction and E’ were significantly lower after therapy than before (P value < 0.001). Heart rate, Q wave, R wave, and S wave (QRS) and QTc were significantly higher after therapy than before therapy (P value<0.001). QT was significantly lower after therapy than before therapy (P value=0.044). QTd was insignificantly different between after therapy and before therapy. Conclusions: Cardiotoxicity is a serious and recognized complication affecting patients with breast cancer undergoing treatment with anthracyclines and cyclophosphamide. These chemotherapeutic agents contribute to significant alterations in heart function and electrical activity, including changes in heart rate, prolongation of the QRS complex and QT intervals, and the emergence of arrhythmias such as ST-T segment changes, atrial fibrillation, and supraventricular tachycardia.
No takes yet. Share an insight, caveat, or question.
Alwasify et al. (2026) conducted an observational in Breast cancer (n=144). Anthracyclines and cyclophosphamide therapy vs. Before therapy was evaluated on Echocardiographic and ECG changes (including ejection fraction, heart rate, QRS, and QTc) (p=<0.001). Anthracyclines and cyclophosphamide therapy in breast cancer patients decreased ejection fraction and increased heart rate, QRS, and QTc intervals.
Synapse has enriched 10 related papers. Consider them for comparative context: